[go: up one dir, main page]

WO1999036545A3 - Adenoviral vectors with modified capsid proteins - Google Patents

Adenoviral vectors with modified capsid proteins Download PDF

Info

Publication number
WO1999036545A3
WO1999036545A3 PCT/US1999/000913 US9900913W WO9936545A3 WO 1999036545 A3 WO1999036545 A3 WO 1999036545A3 US 9900913 W US9900913 W US 9900913W WO 9936545 A3 WO9936545 A3 WO 9936545A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviral vectors
ligands
capsid proteins
target cells
modified capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/000913
Other languages
French (fr)
Other versions
WO1999036545A2 (en
Inventor
Helen Romanczuk
Donna Armentano
Catherine R O'riordan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to EP99903122A priority Critical patent/EP1044274A2/en
Priority to AU23219/99A priority patent/AU2321999A/en
Priority to JP2000540247A priority patent/JP2002508967A/en
Priority to CA002317941A priority patent/CA2317941A1/en
Publication of WO1999036545A2 publication Critical patent/WO1999036545A2/en
Publication of WO1999036545A3 publication Critical patent/WO1999036545A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to adenoviral vectors having modified capsid proteins which comprise heterologous ligands that improve and/or alter the infectious capability of the vector. Such ligands are capable of binding to target cells, and their inclusion into adenoviral vectors facilitates the binding and infectious properties of the vectors. In a preferred embodiment, the ligands are peptides, and the target cells are epithelial cells. The invention is also directed to novel heterologous ligands, to ligand-receptor complexes, and to compositions comprising the adenoviral vectors of the invention. Additional aspects of the invention include methods to use the adenoviral vectors of the invention to deliver transgenes to target cells.
PCT/US1999/000913 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins Ceased WO1999036545A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99903122A EP1044274A2 (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins
AU23219/99A AU2321999A (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins
JP2000540247A JP2002508967A (en) 1998-01-16 1999-01-15 Adenovirus vector with modified capsid protein
CA002317941A CA2317941A1 (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7167498P 1998-01-16 1998-01-16
US60/071,674 1998-01-16

Publications (2)

Publication Number Publication Date
WO1999036545A2 WO1999036545A2 (en) 1999-07-22
WO1999036545A3 true WO1999036545A3 (en) 1999-11-04

Family

ID=22102858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000913 Ceased WO1999036545A2 (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins

Country Status (5)

Country Link
EP (1) EP1044274A2 (en)
JP (1) JP2002508967A (en)
AU (1) AU2321999A (en)
CA (1) CA2317941A1 (en)
WO (1) WO1999036545A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055365A1 (en) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
WO2001018224A1 (en) * 1999-09-08 2001-03-15 Genzyme Corporation Adenoviral vectors modified for increased and persistent expression of the cystic fibrosis transmembrane conductance regulator gene in human airway epithelia
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
AU773019B2 (en) * 1999-09-24 2004-05-13 Uab Research Foundation, The Capsid-modified recombinant adenovirus and methods of use
AU2001234981A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
WO2001072771A2 (en) * 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
AU6368901A (en) * 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
AU2002250081A1 (en) * 2001-02-14 2002-08-28 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
WO2002083880A1 (en) * 2001-04-17 2002-10-24 Vectorlogics, Inc. Mosaic adenoviral vectors
AU2002344190B2 (en) * 2001-05-30 2007-10-18 Transgene S.A. Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
MXPA05013234A (en) * 2003-06-10 2006-03-09 Univ Saskatchewan Chimeric adenovirus capsid proteins.
EP2036980A1 (en) * 2007-09-14 2009-03-18 Gruber, Jens Down regulation of gene expression using virus-like particles charged with nucleic acid
WO2009098492A2 (en) * 2008-02-07 2009-08-13 Andrew Baker Modulation of adenoviral tropism
CZ2008565A3 (en) * 2008-09-15 2009-11-18 Vysoká škola chemicko technologická v Praze Preparation of monoclonal antibodies against FoxP3 protein using modified virus resembling particles of Mason-Pfizer ape virus
WO2012150478A1 (en) * 2010-04-28 2012-11-08 Institut Gustave Roussy Adenovirus vaccine vectors
CN102559758B (en) * 2011-12-16 2014-10-22 陕西师范大学 Vector for preparing adenovirus of which hexon is subjected to genetic modification and method for constructing vector
MX358019B (en) 2012-05-18 2018-08-02 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005201A1 (en) * 1993-08-13 1995-02-23 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995026412A1 (en) * 1994-03-28 1995-10-05 The Uab Research Foundation Ligands added to adenovirus fiber
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1997020575A1 (en) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
FR2761688A1 (en) * 1997-04-02 1998-10-09 Transgene Sa New adenovirus with mutations in the fibre protein to alter binding selectivity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005201A1 (en) * 1993-08-13 1995-02-23 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995026412A1 (en) * 1994-03-28 1995-10-05 The Uab Research Foundation Ligands added to adenovirus fiber
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1997020575A1 (en) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
FR2761688A1 (en) * 1997-04-02 1998-10-09 Transgene Sa New adenovirus with mutations in the fibre protein to alter binding selectivity

Also Published As

Publication number Publication date
JP2002508967A (en) 2002-03-26
WO1999036545A2 (en) 1999-07-22
EP1044274A2 (en) 2000-10-18
CA2317941A1 (en) 1999-07-22
AU2321999A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
WO1999036545A3 (en) Adenoviral vectors with modified capsid proteins
WO2004111248A3 (en) Improved aav vector for gene therapy
EP1304382A3 (en) Production of peptides in plants as viral coat protein fusions
WO2002061071A3 (en) Focused libraries of genetic packages
DE69826661D1 (en) ANTITUMORAL COMPILATION OF IMMUNOGENEOUS POLYPETIDES WITH CHANGED CELL LOCATION
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
CA2285667A1 (en) Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein a
WO2001038357A3 (en) Jaffa, a novel fibroblast growth factor family member and uses therefor
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2002036627A3 (en) Interferons, uses and compositions related thereto
WO2001092547A3 (en) Modified bovine adenovirus having altered tropism
WO1999055831A3 (en) Adenoviral vectors for treating disease
WO2000012710A8 (en) Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
WO2003004636A3 (en) Expression vectors encoding bacteriophage signal peptides
IL146191A0 (en) Viral expression vectors
WO2004108755A3 (en) Chimeric adenovirus capsid proteins
WO2001092299A3 (en) Adenovirus particles with mutagenized fiber proteins
WO2001030966A3 (en) An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
AU2176997A (en) Novel fused protein, gene therefor, recombinant vector, recombinant virus, and its use
WO2001083552A3 (en) Human sez6 nucleic acids and polypeptides
WO2002000857A3 (en) 53320, a human acyltransferase and uses therefor
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
WO2002083902A3 (en) Adenovirus serotype 30 (ad30) fiber protein and uses thereof
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09582509

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2317941

Country of ref document: CA

Ref country code: CA

Ref document number: 2317941

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 540247

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 23219/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999903122

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999903122

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999903122

Country of ref document: EP